Newbury Pharmaceuticals AB (NEWBRY) — Financial Flexibility Index
Newbury Pharmaceuticals AB (NEWBRY) has a Financial Flexibility Index of 0.05x as of February 2026. Free cash flow of Skr2.26 Million (operating CF Skr2.26 Million minus capex Skr0.00) represents 0% of total liabilities (Skr45.96 Million). Also explore Newbury Pharmaceuticals AB equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Newbury Pharmaceuticals AB Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for Newbury Pharmaceuticals AB across 4 annual periods. See Newbury Pharmaceuticals AB (NEWBRY) net asset quality to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for Newbury Pharmaceuticals AB (2021–2024)
Year-by-year free cash flow to debt coverage for Newbury Pharmaceuticals AB. For the full company profile including market capitalisation, see Newbury Pharmaceuticals AB market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | Skr-20.80 Million | Skr-23.71 Million | Skr38.95 Million | ▲ +43.8% |
| 2023 | -0.95x | Skr-22.36 Million | Skr-23.23 Million | Skr23.54 Million | ▼ -283.4% |
| 2022 | 0.52x | Skr9.40 Million | Skr-15.00 Million | Skr18.14 Million | ▼ -88.2% |
| 2021 | 4.38x | Skr19.02 Million | Skr-4.07 Million | Skr4.34 Million | — |